|
1
|
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
|
J Clin Oncol
|
1999
|
1.98
|
|
2
|
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
|
Breast Cancer Res Treat
|
2011
|
1.87
|
|
3
|
Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
|
Ann Oncol
|
2011
|
1.62
|
|
4
|
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
|
Cancer Invest
|
1996
|
1.41
|
|
5
|
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
2005
|
1.32
|
|
6
|
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
|
J Clin Oncol
|
2000
|
1.31
|
|
7
|
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
|
Ann Oncol
|
2005
|
1.28
|
|
8
|
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
|
Lung Cancer
|
1994
|
1.13
|
|
9
|
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
|
Ann Oncol
|
2000
|
1.06
|
|
10
|
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.
|
Ann Oncol
|
2001
|
1.02
|
|
11
|
Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
|
Oncology
|
1998
|
1.00
|
|
12
|
Response of malignant thymoma to erlotinib.
|
Ann Oncol
|
2008
|
0.99
|
|
13
|
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.
|
Semin Oncol
|
1994
|
0.99
|
|
14
|
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed.
|
Cancer Lett
|
2002
|
0.95
|
|
15
|
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
|
Ann Oncol
|
2007
|
0.93
|
|
16
|
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
2007
|
0.92
|
|
17
|
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
|
Hum Mutat
|
2000
|
0.91
|
|
18
|
Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study.
|
Ann Oncol
|
1992
|
0.91
|
|
19
|
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
|
Breast Cancer Res Treat
|
2008
|
0.91
|
|
20
|
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.
|
Eur J Cancer
|
1996
|
0.89
|
|
21
|
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.
|
J Clin Oncol
|
1996
|
0.89
|
|
22
|
Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide.
|
Eur J Nucl Med
|
1998
|
0.89
|
|
23
|
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
|
J Clin Oncol
|
2002
|
0.89
|
|
24
|
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
|
Ann Oncol
|
2004
|
0.88
|
|
25
|
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
|
Oncology
|
1998
|
0.88
|
|
26
|
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
2004
|
0.88
|
|
27
|
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience.
|
Int J Gynecol Cancer
|
2007
|
0.88
|
|
28
|
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
|
Ann Oncol
|
2010
|
0.86
|
|
29
|
Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study.
|
Med Pediatr Oncol
|
1997
|
0.85
|
|
30
|
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
1997
|
0.84
|
|
31
|
Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience.
|
Oncology
|
1999
|
0.83
|
|
32
|
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study.
|
Anticancer Res
|
1998
|
0.83
|
|
33
|
Evaluation of six tumor markers in patients with carcinoma of unknown primary.
|
Med Pediatr Oncol
|
1994
|
0.82
|
|
34
|
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
|
J Clin Oncol
|
2001
|
0.82
|
|
35
|
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
|
Urology
|
2005
|
0.82
|
|
36
|
Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
1999
|
0.81
|
|
37
|
Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience.
|
Oncology
|
2000
|
0.81
|
|
38
|
Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies.
|
J Nucl Med
|
1988
|
0.81
|
|
39
|
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
|
Semin Oncol
|
1997
|
0.81
|
|
40
|
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
|
Med Oncol
|
2000
|
0.81
|
|
41
|
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
|
Cancer Chemother Pharmacol
|
2005
|
0.80
|
|
42
|
Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.
|
Br J Cancer Suppl
|
1990
|
0.80
|
|
43
|
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
|
Oncology
|
2000
|
0.80
|
|
44
|
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.
|
Semin Oncol
|
2000
|
0.80
|
|
45
|
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
|
Br J Cancer
|
2004
|
0.80
|
|
46
|
Human papilloma virus DNA detection in oral lesions in the Greek population.
|
Anticancer Res
|
1999
|
0.80
|
|
47
|
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
|
Cancer Chemother Pharmacol
|
2006
|
0.79
|
|
48
|
Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody.
|
Lancet
|
1996
|
0.79
|
|
49
|
Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
|
Med Pediatr Oncol
|
1996
|
0.79
|
|
50
|
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer.
|
Eur J Cancer
|
1994
|
0.79
|
|
51
|
A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group study.
|
Tumori
|
2000
|
0.78
|
|
52
|
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
|
Cancer Chemother Pharmacol
|
2007
|
0.78
|
|
53
|
Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
|
Oncology
|
1999
|
0.78
|
|
54
|
An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
|
Anticancer Res
|
2001
|
0.78
|
|
55
|
High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study.
|
Med Pediatr Oncol
|
1995
|
0.78
|
|
56
|
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
1998
|
0.77
|
|
57
|
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study.
|
Ann Oncol
|
1997
|
0.77
|
|
58
|
Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co-operative Oncology Group study.
|
Acta Oncol
|
1994
|
0.77
|
|
59
|
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
|
Ann Oncol
|
2005
|
0.77
|
|
60
|
Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
|
Ann Oncol
|
2000
|
0.77
|
|
61
|
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
|
Cancer Invest
|
2003
|
0.77
|
|
62
|
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study.
|
Ann Oncol
|
1997
|
0.77
|
|
63
|
The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
|
Urology
|
2003
|
0.76
|
|
64
|
Molecular markers in extragonadal germ cell tumours: a matched case-control study.
|
Histopathology
|
2007
|
0.76
|
|
65
|
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
|
Lung Cancer
|
2007
|
0.76
|
|
66
|
First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study.
|
Anticancer Res
|
2002
|
0.76
|
|
67
|
Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients.
|
Anticancer Res
|
2001
|
0.76
|
|
68
|
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group.
|
Eur J Cancer
|
1997
|
0.76
|
|
69
|
Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.
|
Anticancer Res
|
2008
|
0.76
|
|
70
|
Immunohistochemical detection of p53 protein in HPV positive oral lesions.
|
Anticancer Res
|
1999
|
0.76
|
|
71
|
Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.
|
Anticancer Res
|
2009
|
0.76
|
|
72
|
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study.
|
Tumori
|
1991
|
0.75
|
|
73
|
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
|
Am J Clin Oncol
|
2004
|
0.75
|
|
74
|
Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma.
|
Am J Clin Oncol
|
1996
|
0.75
|
|
75
|
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study.
|
Oncology
|
1998
|
0.75
|
|
76
|
Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma.
|
Oncology
|
1998
|
0.75
|
|
77
|
Paclitaxel and carboplatin in nonoperable non-small cell lung cancer.
|
Semin Oncol
|
1996
|
0.75
|
|
78
|
Prognostic factors influencing complete response to treatment and survival of patients with nasopharyngeal cancer.
|
Anticancer Res
|
1998
|
0.75
|
|
79
|
Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines.
|
Tumori
|
1993
|
0.75
|
|
80
|
Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
|
J Exp Clin Cancer Res
|
1998
|
0.75
|
|
81
|
5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group.
|
Ann Oncol
|
1997
|
0.75
|
|
82
|
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].
|
Anticancer Res
|
1998
|
0.75
|
|
83
|
Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study.
|
Tumori
|
1996
|
0.75
|
|
84
|
Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.
|
Semin Oncol
|
1997
|
0.75
|
|
85
|
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study.
|
Oncology
|
1996
|
0.75
|
|
86
|
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
|
Cancer Chemother Pharmacol
|
2005
|
0.75
|
|
87
|
Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
|
Semin Oncol
|
1996
|
0.75
|
|
88
|
Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study.
|
Oncology
|
1996
|
0.75
|
|
89
|
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
|
Anticancer Drugs
|
2005
|
0.75
|
|
90
|
The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study.
|
Lung Cancer
|
1994
|
0.75
|
|
91
|
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
|
Oncology
|
2001
|
0.75
|
|
92
|
Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
|
Oncology
|
2002
|
0.75
|
|
93
|
Correlation of MDR 1 expression and CA 125 in ovarian cancer.
|
In Vivo
|
2005
|
0.75
|
|
94
|
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
|
Semin Oncol
|
1997
|
0.75
|
|
95
|
Stevens-Johnson syndrome and epidermal necrolysis after administration of sodium phenytoin with cranial irradiation.
|
Eur J Cancer
|
1993
|
0.75
|
|
96
|
Accelerated bifractionated radiation with concurrent cisplatin administration in locally advanced head and neck cancer: a feasibility study.
|
Tumori
|
1997
|
0.75
|
|
97
|
Monoclonal antibodies in ovarian tumor imaging.
|
Eur J Gynaecol Oncol
|
1988
|
0.75
|
|
98
|
Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
|
Ann Oncol
|
2000
|
0.75
|
|
99
|
Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group Study (HeCOG).
|
J Exp Clin Cancer Res
|
1997
|
0.75
|
|
100
|
Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
|
J Interferon Cytokine Res
|
2000
|
0.75
|
|
101
|
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
|
Ann Oncol
|
1996
|
0.75
|